The clinical significance of markers of endothelial dysfunction (ED) inprogression of idiopathic interstitial pneumonias (IIP) Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011
Clinical significance of serum CA 15-3 in patients with idiopathic interstitial pneumonias Source: Annual Congress 2007 - Interstitial lung disease: diagnostic and therapeutic novelties Year: 2007
Prognostic significance of serum markers in acute exacerbation of idiopathic interstitial pneumonias Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011
Clinical significance of histological UIP pattern in interstitial pneumonia with autoimmune features (IPAF) Source: International Congress 2017 – Novel and old entities Year: 2017
Incidence, clinical pictures and courses of patients with MPO-ANCA positive interstitial pneumonia (IP) of unknown etiology Source: Eur Respir J 2004; 24: Suppl. 48, 505s Year: 2004
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
KL-6/MUC1 in interstitial pneumonia Source: Annual Congress 2005 - Lung-specific serum markers for interstitial lung diseases Year: 2005
Diagnostic mistakes in patients with idiopathic interstitial pneumonias (IIP) Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009
Myositis-specific antibodies in a cohort of idiopathic interstitial pneumonias with suggestive morphologies. Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018
Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Clinical-radiographic-pathologic diagnosis in idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Clinical significance of histological classification of idiopathic interstitial pneumonia Source: Eur Respir J 2002; 19: 275-283 Year: 2002
Myositis-associated interstitial pneumonia (MaIP): Autoantibody associations in patients presenting to pulmonologists and rheumatologists Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013
ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
The prognostic significance of fibroblastic foci in usual interstitial pneumonia and nonspecific interstitial pneumonia Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010
Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
Cystic lesion in myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)- positive interstitial pneumonia: radiological and pathological anaylsis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018
Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003
Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013